1 | V-Fend | - | - | - | - | 1件: 299 299 |
2 | V08CA02 | - | - | - | - | 1件: 13 13 |
3 | V08CA09 | - | - | - | - | 1件: 13 13 |
4 | V1512 | - | - | - | - | 1件: 6 6 |
5 | V1512 and Entacapone | 1件: Entacapone Entacapone | 1件: D00781
D00781
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
6 | V565 | - | - | - | - | 2件: 96 96, 97 |
7 | V81444 | - | - | - | - | 1件: 6 6 |
8 | VA | - | - | - | - | 3件: 90 90, 301, 302 |
9 | Vaccin grippal pandémique H1N1 | - | - | - | - | 1件: 299 299 |
10 | Vaccination | - | - | - | - | 1件: 49 49 |
11 | Vaccination against TBE | - | - | - | - | 1件: 46 46 |
12 | Vaccination with vaccine against hepatitis A and B | - | - | - | - | 1件: 299 299 |
13 | Vaccine | - | - | - | - | 1件: 49 49 |
14 | Vaccine Vivotif + Vaccine Dukoral | 2件: Recombinant Cholera Toxin B Subunit Recombinant Cholera Toxin B Subunit, Typhoid Vaccine Live | - | - | - | 1件: 97 97 |
15 | Vaccine Vivotif + Vaccine Dukoral + oats | 3件: Oat Oat, Recombinant Cholera Toxin B Subunit, Typhoid Vaccine Live | - | - | - | 1件: 97 97 |
16 | VACCINO CONTRO IL MEMINGOCOCCO DI GRUPPO B | - | - | - | - | 3件: 61 61, 62, 66 |
17 | VACCINO HAEMOPHILUS INFLUENZAE B CONIUGATO CON TOSSOIDETETANICO | - | - | - | - | 2件: 61 61, 62 |
18 | VACCINO PNEUMOCOCCICO | - | - | - | - | 2件: 62 62, 66 |
19 | VACCINO PNEUMOCOCCICO SACCARIDICO | - | - | - | - | 1件: 14 14 |
20 | VACCINO POLISACCARIDICO ANTI-MENINGOCOCCICO (A.C.Y E W-135) | - | - | - | - | 3件: 61 61, 62, 66 |
21 | Vaginal estriol | 1件: Estriol Estriol | 2件: D00185
D00185
,
D01986
| 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 13 13 |
22 | VAL-1221 | - | - | - | - | 1件: 256 256 |
23 | Valacyclovir | 1件: Valaciclovir Valaciclovir | 3件: D00398
D00398
,
D08664
,
D10518
| - | - | 1件: 65 65 |
24 | Valbenazine | 1件: Valbenazine Valbenazine | 1件: D10675
D10675
| 1件: SLC18A2 SLC18A2 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 8 8 |
25 | Valdecoxib | 1件: Valdecoxib Valdecoxib | 1件: D02709
D02709
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
26 | Valerian | 1件: Valerian Valerian | - | - | - | 1件: 6 6 |
27 | Valganciclovir | 1件: Valganciclovir Valganciclovir | 1件: D02495
D02495
| - | - | 6件: 28 28, 60, 85, 97, 299, 331 |
28 | Valganciclovir (VGC) | 1件: Valganciclovir Valganciclovir | 1件: D02495
D02495
| - | - | 1件: 331 331 |
29 | Valganciclovir [Valcyte] | 1件: Valganciclovir Valganciclovir | 1件: D02495
D02495
| - | - | 1件: 299 299 |
30 | Valiloxybate | - | - | - | - | 1件: 6 6 |
31 | Valproate | 1件: Valproic acid Valproic acid | 1件: D00399
D00399
| 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 6件: 2 2, 3, 90, 102, 233, 256 |
32 | VALPROATE SODIUM | 1件: Valproic acid Valproic acid | 1件: D00399
D00399
| 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 3 3 |
33 | Valproate, Levocarnitine | 2件: Levocarnitine Levocarnitine, Valproic acid | 4件: D00399
D00399
,
D02030
,
D02176
,
D04713
| 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 3 3 |
34 | Valproic Acid | 1件: Valproic acid Valproic acid | 1件: D00399
D00399
| 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 10件: 3 3, 5, 26, 34, 65, 89, 90, 222, 256, 331 |
35 | Valproic Acid (VPA) | 1件: Valproic acid Valproic acid | 1件: D00399
D00399
| 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 3 3 |
36 | Valproic Acid and Levocarnitine | 2件: Levocarnitine Levocarnitine, Valproic acid | 4件: D00399
D00399
,
D02030
,
D02176
,
D04713
| 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 3 3 |
37 | Valproid acid plus corticosteroids | - | - | - | - | 1件: 26 26 |
38 | Valsartan | 1件: Valsartan Valsartan | 1件: D00400
D00400
| 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 7件: 57 57, 58, 66, 75, 218, 222, 224 |
39 | Vamarolone | - | - | - | - | 1件: 113 113 |
40 | Vaminolac | - | - | - | - | 1件: 97 97 |
41 | Vaminolac, komb. | - | - | - | - | 1件: 97 97 |
42 | Vamorolone | 1件: Vamorolone Vamorolone | 1件: D11000
D11000
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 97 97, 113 |
43 | Vamorolone 0.25 mg/day/day | 1件: Vamorolone Vamorolone | 1件: D11000
D11000
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 |
44 | Vamorolone 0.25 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: D11000
D11000
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 |
45 | Vamorolone 0.75 mg/day/day | 1件: Vamorolone Vamorolone | 1件: D11000
D11000
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 |
46 | Vamorolone 0.75 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: D11000
D11000
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 |
47 | Vamorolone 2.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: D11000
D11000
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 |
48 | Vamorolone 2.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: D11000
D11000
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 |
49 | Vamorolone 4% suspension for oral dosing | 1件: Vamorolone Vamorolone | 1件: D11000
D11000
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
50 | Vamorolone 6.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: D11000
D11000
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 |
51 | Vamorolone 6.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: D11000
D11000
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 |
52 | Vancomycin | 1件: Vancomycin Vancomycin | 2件: D00212
D00212
,
D00926
| - | - | 7件: 46 46, 70, 94, 96, 97, 296, 299 |
53 | Vancomycin hydrochloride inhalation powder | 1件: Vancomycin Vancomycin | 2件: D00212
D00212
,
D00926
| - | - | 1件: 299 299 |
54 | Vancomycin inhalation powder | 1件: Vancomycin Vancomycin | 2件: D00212
D00212
,
D00926
| - | - | 1件: 299 299 |
55 | Vancomycin Pre-Treat | 1件: Vancomycin Vancomycin | 2件: D00212
D00212
,
D00926
| - | - | 1件: 97 97 |
56 | Vancomycin Pre-Treatment | 1件: Vancomycin Vancomycin | 2件: D00212
D00212
,
D00926
| - | - | 1件: 97 97 |
57 | Vanguard 360 TiNbN Femur with PS bearing | - | - | - | - | 1件: 46 46 |
58 | Vanguard 360 TiNbN Femur with PSC bearing | - | - | - | - | 1件: 46 46 |
59 | Vanguard DA 360 | - | - | - | - | 1件: 46 46 |
60 | Vanguard SSK 360 with PS Bearing | - | - | - | - | 1件: 46 46 |
61 | Vanguard SSK 360 with PSC bearing | - | - | - | - | 1件: 46 46 |
62 | Vantobra (tobramycin) | 1件: Tobramycin Tobramycin | 2件: D00063
D00063
,
D02542
| - | - | 1件: 299 299 |
63 | Vardenafil | 1件: Vardenafil Vardenafil | 3件: D02731
D02731
,
D03260
,
D08668
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 3件: 13 13, 86, 299 |
64 | Vardenafil (hidrocloride) | 1件: Vardenafil Vardenafil | 3件: D02731
D02731
,
D03260
,
D08668
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
65 | Vardenafilo | 1件: Vardenafil Vardenafil | 3件: D02731
D02731
,
D03260
,
D08668
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
66 | VARDENAFILO HIDROCLORURO | 1件: Vardenafil Vardenafil | 3件: D02731
D02731
,
D03260
,
D08668
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
67 | VARENICLINE | 1件: Varenicline Varenicline | 1件: D08669
D08669
| 2件: CHRNA4 CHRNA4, CHRNB2 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction 💬 | 2件: 6 6, 18 |
68 | VARENICLINE TARTRATE | 1件: Varenicline Varenicline | 1件: D08669
D08669
| 2件: CHRNA4 CHRNA4, CHRNB2 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction 💬 | 1件: 6 6 |
69 | VARI | - | - | - | - | 2件: 62 62, 274 |
70 | Variation of behaviors of Parkinson's disease | - | - | - | - | 1件: 6 6 |
71 | Varicella Zoster Vaccine | - | - | - | - | 1件: 46 46 |
72 | Various | - | - | - | - | 1件: 95 95 |
73 | Vaseline | - | - | - | - | 1件: 51 51 |
74 | Vasoactive intestinal peptide | - | - | - | - | 1件: 85 85 |
75 | Vasomera (PB1046) Injection | - | - | - | - | 1件: 86 86 |
76 | Vasopressin | 1件: Vasopressin Vasopressin | 1件: D00101
D00101
| 3件: AVPR1A AVPR1A, AVPR1B, AVPR2 💬 | 5件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption 💬 | 1件: 210 210 |
77 | Vasopressin, Arginine | 2件: Arginine Arginine, Vasopressin | 2件: D00101
D00101
,
D02982
| 3件: AVPR1A AVPR1A, AVPR1B, AVPR2 💬 | 5件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption 💬 | 1件: 210 210 |
78 | Vastarel | - | - | - | - | 2件: 2 2, 58 |
79 | Vastarel 20mg film coated tablets | - | - | - | - | 1件: 58 58 |
80 | Vatelizumab | 1件: Vatelizumab Vatelizumab | - | - | - | 2件: 13 13, 97 |
81 | VATIQUINONE | 1件: Vatiquinone Vatiquinone | 1件: D10407
D10407
| - | - | 2件: 18 18, 21 |
82 | Vaxzevria | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 1件: 299 299 |
83 | Vaxzevria suspension for injection COVID-19 Vaccine (ChAdOx1-S | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 1件: 299 299 |
84 | VAY736 | - | - | - | - | 7件: 13 13, 35, 46, 49, 53, 85, 95 |
85 | VAY736 antibody | - | - | - | - | 1件: 53 53 |
86 | VAY736 higher dose | - | - | - | - | 1件: 53 53 |
87 | VAY736 lower dose | - | - | - | - | 1件: 53 53 |
88 | VB-201 | 1件: VB-201 VB-201 | - | - | - | 1件: 97 97 |
89 | VB-201 160mg | 1件: VB-201 VB-201 | - | - | - | 1件: 97 97 |
90 | VB119 | - | - | - | - | 1件: 222 222 |
91 | VB13S1 | - | - | - | - | 1件: 13 13 |
92 | VB5S2 | - | - | - | - | 1件: 13 13 |
93 | VB6S5 | - | - | - | - | 1件: 13 13 |
94 | VBP15 | - | - | - | - | 1件: 113 113 |
95 | VE202 | - | - | - | - | 1件: 97 97 |
96 | Vector viral adenoasociado de serotipo 9 que contiene el gen de la sulfamidasa humana | - | - | - | - | 1件: 19 19 |
97 | VEDOLIZUMAB | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 3件: 94 94, 96, 97 |
98 | Vedolizumab (Genetical Recombination) | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 96 96 |
99 | Vedolizumab 108 mg SC | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 |
100 | Vedolizumab 300 mg | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 |
101 | Vedolizumab 300 MG Injection [Entyvio] | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 96 96 |
102 | Vedolizumab 300 mg IV | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 |
103 | Vedolizumab Injection | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 |
104 | Vedolizumab Intravenous (IV), Vedolizumab Subcutaneous (SC), Placebo IV | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 |
105 | Vedolizumab intravenous injection | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 |
106 | Vedolizumab IV | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 3件: 94 94, 96, 97 |
107 | Vedolizumab IV (Entyvio¿) | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 96 96 |
108 | Vedolizumab IV (Entyvio™) | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 96 96 |
109 | Vedolizumab IV 300 mg | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 96 96 |
110 | Vedolizumab IV, Placebo IV, Placebo SC | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 |
111 | Vedolizumab IV, Placebo SC | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 |
112 | Vedolizumab SC | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 |
113 | Vedolizumab SC 108 mg | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 |
114 | Vedolizumab subcutaneous injection | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 |
115 | Vedolizumab, Ustekinumab, or Tofacitinib | 3件: Tofacitinib Tofacitinib, Ustekinumab, Vedolizumab | 3件: D08083
D08083
,
D09214
,
D09970
| 9件: IL12A IL12A, IL12B, IL23A, ITGA4, ITGB7, JAK1, JAK2, JAK3, TYK2 💬 | 65件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, Arrhythmogenic right ventricular cardiomyopathy, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, ECM-receptor interaction, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Focal adhesion, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pertussis, Primary immunodeficiency, Prolactin signaling pathway, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Yersinia infection 💬 | 1件: 97 97 |
116 | Vedolizumab-800CW | 1件: Vedolizumab Vedolizumab | 1件: D08083
D08083
| 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 96 96 |
117 | VEDROP | 1件: Tocofersolan Tocofersolan | 1件: D06174
D06174
| - | - | 1件: 299 299 |
118 | VEDULIZUMAB | - | - | - | - | 1件: 97 97 |
119 | Vehice Control | - | - | - | - | 1件: 96 96 |
120 | Vehicle | - | - | - | - | 4件: 6 6, 36, 160, 192 |
121 | Vehicle (SD-101 0%) | - | - | - | - | 1件: 36 36 |
122 | Vehicle Control | - | - | - | - | 1件: 53 53 |
123 | Vehicle Cream | - | - | - | - | 1件: 36 36 |
124 | Vehicle eye drops | - | - | - | - | 1件: 90 90 |
125 | Vehicle Gel | - | - | - | - | 2件: 13 13, 34 |
126 | Vehicle of ADX-102 Topical Dermal Cream | - | - | - | - | 1件: 160 160 |
127 | Vehicle ophthalmic solution | - | - | - | - | 1件: 53 53 |
128 | Vehicle Topical Gel | - | - | - | - | 1件: 36 36 |
129 | VELAGLUCERASE ALFA | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: D09029
D09029
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
130 | Velaglucerase alfa (VPRIV) | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: D09029
D09029
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
131 | Velaglucerasi alfa | - | - | - | - | 1件: 19 19 |
132 | Velamox | - | - | - | - | 1件: 11 11 |
133 | Velcade | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 3件: 11 11, 28, 61 |
134 | VELCADE*1FL 3,5MG | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 |
135 | VELCADE*EV 1FL 3,5MG 1MG/ML | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 61 61 |
136 | Velcade® | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 11 11 |
137 | Veldona | - | - | - | - | 1件: 56 56 |
138 | Veldona, | - | - | - | - | 1件: 56 56 |
139 | Veledimex | 1件: Veledimex Veledimex | 1件: D10678
D10678
| - | - | 1件: 51 51 |
140 | Veletri | 1件: Epoprostenol Epoprostenol | 2件: D00106
D00106
,
D01337
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
141 | VELMANASE ALFA | 1件: Velmanase alfa Velmanase alfa | 1件: D11024
D11024
| 1件: MAN2B1 MAN2B1 💬 | 2件: Lysosome Lysosome, Other glycan degradation 💬 | 1件: 19 19 |
142 | Velmanase Alfa (e.g. Lamazym) | 1件: Velmanase alfa Velmanase alfa | 1件: D11024
D11024
| 1件: MAN2B1 MAN2B1 💬 | 2件: Lysosome Lysosome, Other glycan degradation 💬 | 1件: 19 19 |
143 | Veltuzumab | 1件: Veltuzumab Veltuzumab | 1件: D09031
D09031
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 |
144 | Veltuzumab solution 75mg/ml | 1件: Veltuzumab Veltuzumab | 1件: D09031
D09031
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 |
145 | Velusetrag | 1件: Velusetrag Velusetrag | 1件: D09693
D09693
| 1件: HTR4 HTR4 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, cAMP signaling pathway 💬 | 1件: 99 99 |
146 | Venetoclax | 1件: Venetoclax Venetoclax | 1件: D10679
D10679
| 1件: BCL2 BCL2 💬 | 43件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Amyotrophic lateral sclerosis, Apoptosis, Apoptosis - multiple species, Autophagy - animal, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Epstein-Barr virus infection, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Gastric cancer, HIF-1 signaling pathway, Hedgehog signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, JAK-STAT signaling pathway, Lipid and atherosclerosis, Measles, MicroRNAs in cancer, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Prostate cancer, Protein processing in endoplasmic reticulum, Salmonella infection, Shigellosis, Small cell lung cancer, Sphingolipid signaling pathway, Toxoplasmosis, Tuberculosis, p53 signaling pathway 💬 | 1件: 28 28 |
147 | Venglustat | 1件: Venglustat Venglustat | 1件: D11633
D11633
| 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 3件: 6 6, 19, 67 |
148 | Venglustat (GZ402671) | 1件: Venglustat Venglustat | 1件: D11633
D11633
| 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 |
149 | Venglustat GZ/SAR402671 | 1件: Venglustat Venglustat | 1件: D11633
D11633
| 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 2件: 6 6, 67 |
150 | Venglustat GZ402671 | 1件: Venglustat Venglustat | 1件: D11633
D11633
| 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 2件: 19 19, 67 |
151 | Venglustat malate | 1件: Venglustat Venglustat | 1件: D11633
D11633
| 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 3件: 6 6, 19, 67 |
152 | Venglustat malato | 1件: Venglustat Venglustat | 1件: D11633
D11633
| 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 2件: 19 19, 67 |
153 | Venipunctures | - | - | - | - | 1件: 84 84 |
154 | Venlafaxin Hexal | - | - | - | - | 1件: 13 13 |
155 | Venlafaxine | 1件: Venlafaxine Venlafaxine | 2件: D00821
D00821
,
D08670
| 2件: SLC6A2 SLC6A2, SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 3件: 6 6, 13, 46 |
156 | VENLAFAXINE HYDROCHLORIDE | 1件: Venlafaxine Venlafaxine | 2件: D00821
D00821
,
D08670
| 2件: SLC6A2 SLC6A2, SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 2件: 13 13, 46 |
157 | Venous blood sample | - | - | - | - | 1件: 46 46 |
158 | Ventavis | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
159 | Ventavis (Iloprost, BAYQ6256) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
160 | Ventavis 10 | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
161 | Ventavis(Iloprost) | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
162 | Ventolin | 1件: Salbutamol Salbutamol | 1件: D02147
D02147
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 299 299 |
163 | Ventoline | - | - | - | - | 1件: 111 111 |
164 | Ventoline oral solution 0,4mg/ml | - | - | - | - | 1件: 111 111 |
165 | Ventoline tablet 2mg | - | - | - | - | 1件: 111 111 |
166 | Ventolin® Evohaler | 1件: Salbutamol Salbutamol | 1件: D02147
D02147
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 299 299 |
167 | Ventolin¿ Evohaler¿ | 1件: Salbutamol Salbutamol | 1件: D02147
D02147
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 299 299 |
168 | Venus Versa | - | - | - | - | 1件: 265 265 |
169 | Verapamil | 1件: Verapamil Verapamil | 2件: D00619
D00619
,
D02356
| 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 96 96, 140, 167 |
170 | Verapamil SR | 1件: Verapamil Verapamil | 2件: D00619
D00619
,
D02356
| 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 167 167 |
171 | Verde de Indocianina (Indocyanine Green) | 1件: Indocyanine green Indocyanine green | 1件: D01342
D01342
| - | - | 1件: 235 235 |
172 | Verdiperstat | 1件: Verdiperstat Verdiperstat | 1件: D11684
D11684
| 1件: MPO MPO 💬 | 5件: Acute myeloid leukemia Acute myeloid leukemia, Drug metabolism - other enzymes, Neutrophil extracellular trap formation, Phagosome, Transcriptional misregulation in cancer 💬 | 3件: 2 2, 17, 127 |
173 | Veregen | 1件: Sinecatechins Sinecatechins | 1件: D08997
D08997
| - | - | 1件: 160 160 |
174 | VEREGEN(R) | 1件: Sinecatechins Sinecatechins | 1件: D08997
D08997
| - | - | 1件: 160 160 |
175 | Verorab® (PVRV | - | - | - | - | 1件: 65 65 |
176 | Versus hydroxychloroquine | 1件: Hydroxychloroquine Hydroxychloroquine | 1件: D08050
D08050
| - | - | 1件: 49 49 |
177 | Verum arm receiving Gilenya® | - | - | - | - | 1件: 13 13 |
178 | Verum arm receiving Vitamin D oil | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 |
179 | VESANOID | 1件: Tretinoin Tretinoin | 1件: D00094
D00094
| 3件: PML PML, RARA, RARB 💬 | 12件: Acute myeloid leukemia Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 75 75 |
180 | VESIcare 10Mg Tablet | - | - | - | - | 1件: 13 13 |
181 | Vessel | - | - | - | - | 4件: 13 13, 51, 271, 288 |
182 | Vestronidase alfa | 1件: Vestronidase alfa Vestronidase alfa | 1件: D11004
D11004
| 1件: GUSB GUSB 💬 | 8件: Ascorbate and aldarate metabolism Ascorbate and aldarate metabolism, Biosynthesis of cofactors, Drug metabolism - other enzymes, Glycosaminoglycan degradation, Lysosome, Metabolic pathways, Pentose and glucuronate interconversions, Porphyrin metabolism 💬 | 1件: 19 19 |
183 | Vett Lentiviral con gene ABCA4 | - | - | - | - | 1件: 301 301 |
184 | VEYONDI 650IU powder and solvent for solution for injection | - | - | - | - | 1件: 288 288 |
185 | Veyvondi | 1件: Vonicog alfa Vonicog alfa | 1件: D08681
D08681
| - | - | 1件: 288 288 |
186 | VEYVONDI 1300I IU powder and solvent for solution for injection | 1件: Vonicog alfa Vonicog alfa | 1件: D08681
D08681
| - | - | 1件: 288 288 |
187 | VEYVONDI 1300IU powder and solvent for solution for injection | 1件: Vonicog alfa Vonicog alfa | 1件: D08681
D08681
| - | - | 1件: 288 288 |
188 | VEYVONDI 650IU powder and solvent for solution for injection | 1件: Vonicog alfa Vonicog alfa | 1件: D08681
D08681
| - | - | 1件: 288 288 |
189 | Vfend | 1件: Voriconazole Voriconazole | 1件: D00578
D00578
| - | - | 1件: 299 299 |
190 | VFEND 40 mg/ml powder for oral suspension | 1件: Voriconazole Voriconazole | 1件: D00578
D00578
| - | - | 1件: 299 299 |
191 | VGB-ST | - | - | - | - | 1件: 145 145 |
192 | VGB-ST soluble tablets | - | - | - | - | 1件: 145 145 |
193 | VIAGRA | 1件: Sildenafil Sildenafil | 2件: D02229
D02229
,
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 3件: 86 86, 96, 225 |
194 | VIALEBEX | - | - | - | - | 1件: 96 96 |
195 | Vialebex 200mg | - | - | - | - | 1件: 96 96 |
196 | Viaskin Milk 500 mcg | 1件: Cow milk Cow milk | - | - | - | 1件: 98 98 |
197 | VIB4920 | - | - | - | - | 2件: 46 46, 53 |
198 | VIB7734 | - | - | - | - | 4件: 49 49, 50, 51, 53 |
199 | VIB7734, MEDI7734 | - | - | - | - | 1件: 49 49 |
200 | VIBEX MTX | - | - | - | - | 1件: 46 46 |
201 | Vibrox | - | - | - | - | 1件: 167 167 |
202 | Vibrox 100mg Capsules | - | - | - | - | 1件: 167 167 |
203 | Video calling program Better-close | - | - | - | - | 1件: 13 13 |
204 | Video game therapy | - | - | - | - | 1件: 13 13 |
205 | Videofluoroscopic Swallowing Study | - | - | - | - | 1件: 2 2 |
206 | Videofluoroscopic Swallowing Study (VFSS) | - | - | - | - | 1件: 2 2 |
207 | Vidofludimus | 1件: Vidofludimus Vidofludimus | - | - | - | 5件: 13 13, 46, 94, 96, 97 |
208 | VIDOFLUDIMUS CALCIUM | 2件: Calcium Calcium, Vidofludimus | - | - | - | 4件: 13 13, 94, 96, 97 |
209 | Vidofludimus calcium dihydrate | 2件: Calcium Calcium, Vidofludimus | - | - | - | 1件: 97 97 |
210 | VIGABATRIN | 1件: Vigabatrin Vigabatrin | 1件: D00535
D00535
| 1件: ABAT ABAT 💬 | 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 2件: 145 145, 158 |
211 | Vigabatrin (Sabril) | 1件: Vigabatrin Vigabatrin | 1件: D00535
D00535
| 1件: ABAT ABAT 💬 | 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 158 158 |
212 | Vigabatrin Tablets | 1件: Vigabatrin Vigabatrin | 1件: D00535
D00535
| 1件: ABAT ABAT 💬 | 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 145 145 |
213 | Vigabatrin: Vigabatrin new ST formulation then Sabril® | 1件: Vigabatrin Vigabatrin | 1件: D00535
D00535
| 1件: ABAT ABAT 💬 | 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 145 145 |
214 | Vigantol | - | - | - | - | 4件: 13 13, 65, 96, 97 |
215 | Vigantol Oel | - | - | - | - | 3件: 13 13, 96, 97 |
216 | Vigantol Oel TM | - | - | - | - | 2件: 96 96, 97 |
217 | VIGANTOL OIL | - | - | - | - | 1件: 13 13 |
218 | VigantOL oil plus interferon beta-1a (Rebif) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
219 | Vigantol® Oil | - | - | - | - | 1件: 13 13 |
220 | Vigantol® Öl 20.000 I.E./ml | - | - | - | - | 1件: 13 13 |
221 | Vilobelimab | 1件: Vilobelimab Vilobelimab | 1件: D11838
D11838
| 1件: C5 C5 💬 | 10件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 2件: 43 43, 44 |
222 | VILTOLARSEN | 1件: Viltolarsen Viltolarsen | 1件: D11528
D11528
| 1件: DMD DMD 💬 | 4件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬 | 1件: 113 113 |
223 | Vimizim® (elosulfase alfa) | 1件: Elosulfase alfa Elosulfase alfa | 1件: D10333
D10333
| 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 |
224 | VIMOVO 250/20 | - | - | - | - | 1件: 107 107 |
225 | VIMOVO 375/20 | - | - | - | - | 1件: 107 107 |
226 | VIMOVO 500/20 | - | - | - | - | 1件: 107 107 |
227 | Vinblastine | 1件: Vinblastine Vinblastine | 2件: D01068
D01068
,
D08675
| 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 2件: 34 34, 65 |
228 | Vinblastine sulfate | 2件: Sulfate ion Sulfate ion, Vinblastine | 2件: D01068
D01068
,
D08675
| 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 34 34 |
229 | VINBLASTINE SULPHATE | 1件: Vinblastine Vinblastine | 2件: D01068
D01068
,
D08675
| 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 34 34 |
230 | Vinblastine, vincristine, prednisone, daunorubicin | 4件: Daunorubicin Daunorubicin, Prednisone, Vinblastine, Vincristine | 7件: D00473
D00473
,
D01068
,
D01264
,
D02197
,
D07776
,
D08675
,
D08679
| 12件: NR3C1 NR3C1, TOP2A, TOP2B, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Platinum drug resistance, Prion disease, Salmonella infection 💬 | 1件: 65 65 |
231 | Vincristine | 1件: Vincristine Vincristine | 2件: D02197
D02197
,
D08679
| 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 4件: 26 26, 34, 65, 331 |
232 | Vincristine Sulfate | 2件: Sulfate ion Sulfate ion, Vincristine | 2件: D02197
D02197
,
D08679
| 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 2件: 26 26, 34 |
233 | Vincristine Sulfate (Oncovin) | 2件: Sulfate ion Sulfate ion, Vincristine | 2件: D02197
D02197
,
D08679
| 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 34 34 |
234 | ViNeuro | - | - | - | - | 1件: 6 6 |
235 | VIOKASE 16 | - | - | - | - | 1件: 298 298 |
236 | Viokase 16 (pancrelipase) + Nexium | 2件: Esomeprazole Esomeprazole, Pancrelipase | 5件: D01984
D01984
,
D04056
,
D05349
,
D07917
,
D09339
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 298 298 |
237 | Viokase® 16 | - | - | - | - | 1件: 298 298 |
238 | VIP | - | - | - | - | 3件: 49 49, 51, 86 |
239 | Viral load driven treatment interruption | - | - | - | - | 1件: 265 265 |
240 | VIREAD - 245 MG 30 COMPRESSE RIVESTITE CON FILM IN FLACONE USO ORALE | - | - | - | - | 1件: 46 46 |
241 | VIREAD 30 CPR 245 MG | - | - | - | - | 1件: 46 46 |
242 | VIS649 | - | - | - | - | 1件: 66 66 |
243 | Viscous/swallowed budesonide | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
244 | Visilizumab | 1件: Visilizumab Visilizumab | 1件: D06314
D06314
| 3件: CD3D CD3D, CD3E, CD3G 💬 | 11件: Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 2件: 96 96, 97 |
245 | Visilizumab (Nuvion) | 1件: Visilizumab Visilizumab | 1件: D06314
D06314
| 3件: CD3D CD3D, CD3E, CD3G 💬 | 11件: Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 97 97 |
246 | VISMODEGIB | 1件: Vismodegib Vismodegib | 1件: D09992
D09992
| 1件: SMO SMO 💬 | 5件: Axon guidance Axon guidance, Basal cell carcinoma, Hedgehog signaling pathway, Pathways in cancer, Proteoglycans in cancer 💬 | 1件: 85 85 |
247 | Visual field testing | - | - | - | - | 1件: 19 19 |
248 | Vit C Vit E Zn Se | - | - | - | - | 1件: 113 113 |
249 | Vit D | - | - | - | - | 1件: 227 227 |
250 | Vitamin A | 1件: Vitamin A Vitamin A | 2件: D00069
D00069
,
D06543
| 2件: RARA RARA, RARB 💬 | 8件: Acute myeloid leukemia Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 3件: 13 13, 53, 90 |
251 | Vitamin AD sig: 1 tablet/tid | - | - | - | - | 1件: 90 90 |
252 | Vitamin B sig: 10mg/tid | - | - | - | - | 1件: 90 90 |
253 | Vitamin B1 | 1件: Thiamine Thiamine | 1件: D08580
D08580
| - | - | 1件: 145 145 |
254 | Vitamin B12 | 1件: Cyanocobalamin Cyanocobalamin | 4件: D00166
D00166
,
D03615
,
D03616
,
D03617
| - | - | 4件: 6 6, 201, 229, 299 |
255 | Vitamin B12 Supplementation | 1件: Cyanocobalamin Cyanocobalamin | 4件: D00166
D00166
,
D03615
,
D03616
,
D03617
| - | - | 1件: 6 6 |
256 | Vitamin B12, B9, B6, C supplementation | 1件: Cyanocobalamin Cyanocobalamin | 4件: D00166
D00166
,
D03615
,
D03616
,
D03617
| - | - | 1件: 229 229 |
257 | Vitamin B2 | 1件: Riboflavin Riboflavin | 3件: D00050
D00050
,
D01622
,
D01913
| - | - | 1件: 97 97 |
258 | Vitamin B3 | - | - | - | - | 2件: 65 65, 107 |
259 | Vitamin B6 | 1件: Pyridoxine Pyridoxine | 2件: D02179
D02179
,
D08454
| - | - | 2件: 6 6, 206 |
260 | Vitamin B7 | 1件: Biotin Biotin | 1件: D00029
D00029
| - | - | 1件: 8 8 |
261 | Vitamin C | 1件: Ascorbic acid Ascorbic acid | 1件: D00018
D00018
| - | - | 6件: 10 10, 192, 206, 210, 211, 212 |
262 | Vitamin C 10mg/Kg Vitamin E 10 mg/Kg | 2件: Ascorbic acid Ascorbic acid, Vitamin E | 2件: D00018
D00018
,
D02331
| - | - | 1件: 206 206 |
263 | Vitamin D | 1件: Vitamin D Vitamin D | - | - | - | 24件: 3 3, 13, 15, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 98, 179, 222, 228, 235, 256, 274, 298, 299 |
264 | Vitamin D 100ug | 1件: Vitamin D Vitamin D | - | - | - | 1件: 298 298 |
265 | Vitamin D 10ug | 1件: Vitamin D Vitamin D | - | - | - | 1件: 298 298 |
266 | Vitamin D 2 | 1件: Vitamin D Vitamin D | - | - | - | 1件: 46 46 |
267 | Vitamin D 25(OH)D | 1件: Vitamin D Vitamin D | - | - | - | 1件: 49 49 |
268 | Vitamin D drops | 1件: Vitamin D Vitamin D | - | - | - | 2件: 96 96, 97 |
269 | Vitamin D in arm B | 1件: Vitamin D Vitamin D | - | - | - | 1件: 46 46 |
270 | Vitamin D Oil | 1件: Vitamin D Vitamin D | - | - | - | 1件: 299 299 |
271 | Vitamin D Powder | 1件: Vitamin D Vitamin D | - | - | - | 1件: 299 299 |
272 | Vitamin D2 | 1件: Ergocalciferol Ergocalciferol | 1件: D00187
D00187
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 3件: 49 49, 84, 299 |
273 | Vitamin D2 ( calciferol ) | 2件: Ergocalciferol Ergocalciferol, Vitamin D | 1件: D00187
D00187
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 |
274 | Vitamin D3 | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 12件: 6 6, 13, 20, 46, 49, 51, 53, 60, 65, 96, 97, 299 |
275 | Vitamin D3 - high dose | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 6 6 |
276 | Vitamin D3 3000 UI daily | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 |
277 | Vitamin D3 400 IU | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 |
278 | Vitamin D3 4000 UI daily | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 |
279 | Vitamin D3 6000 IU | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 |
280 | Vitamin D3 800 UI/day then 800 UI/day | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 |
281 | Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 |
282 | Vitamin E | 1件: Vitamin E Vitamin E | 1件: D02331
D02331
| - | - | 11件: 2 2, 6, 13, 20, 46, 90, 96, 97, 206, 299, 317 |
283 | VITAMIN E - TGPS | 1件: Vitamin E Vitamin E | 1件: D02331
D02331
| - | - | 1件: 299 299 |
284 | Vitamin E 800IU | 1件: Vitamin E Vitamin E | 1件: D02331
D02331
| - | - | 2件: 96 96, 97 |
285 | Vitamin E supplement | 1件: Vitamin E Vitamin E | 1件: D02331
D02331
| - | - | 1件: 317 317 |
286 | Vitamin E/Selenium | 2件: Selenium Selenium, Vitamin E | 1件: D02331
D02331
| - | - | 1件: 13 13 |
287 | Vitamin K | 1件: Phylloquinone Phylloquinone | 1件: D00148
D00148
| - | - | 5件: 13 13, 46, 96, 97, 299 |
288 | Vitamin K 10 mg | 1件: Phylloquinone Phylloquinone | 1件: D00148
D00148
| - | - | 2件: 96 96, 97 |
289 | Vitamin K supplementation, dose #1 | 1件: Phylloquinone Phylloquinone | 1件: D00148
D00148
| - | - | 1件: 299 299 |
290 | Vitamin K supplementation, dose #2 | 1件: Phylloquinone Phylloquinone | 1件: D00148
D00148
| - | - | 1件: 299 299 |
291 | Vitamin K1 | 1件: Phylloquinone Phylloquinone | 1件: D00148
D00148
| - | - | 1件: 96 96 |
292 | Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1 | 1件: Choline Choline | 1件: D07690
D07690
| - | - | 1件: 299 299 |
293 | Vitamina D e calcio | 1件: Calcium Calcium | - | - | - | 1件: 274 274 |
294 | VITAMINA D3 KERN PHARMA SOLUCIÓN OLEOSA | - | - | - | - | 1件: 13 13 |
295 | Vitamins: B6, B12, and folate | 1件: Folic acid Folic acid | 1件: D00070
D00070
| - | - | 1件: 49 49 |
296 | VIUSID/ALZER | - | - | - | - | 1件: 6 6 |
297 | Vivaglobin | - | - | - | - | 2件: 14 14, 65 |
298 | ViviGen Cellular Bone Matrix | - | - | - | - | 1件: 70 70 |
299 | Vivomixx probiotics | - | - | - | - | 1件: 51 51 |
300 | Vivotif | 1件: Typhoid Vaccine Live Typhoid Vaccine Live | - | - | - | 1件: 97 97 |
301 | Vizamyl | 1件: Flutemetamol (18F) Flutemetamol (18F) | - | - | - | 3件: 5 5, 7, 127 |
302 | Vizamyl (flutemetamol(F-18)) | 2件: Flutemetamol Flutemetamol, Flutemetamol (18F) | - | - | - | 3件: 5 5, 7, 127 |
303 | VK0214 | - | - | - | - | 1件: 20 20 |
304 | VM106 | - | - | - | - | 1件: 65 65 |
305 | VM202 | - | - | - | - | 1件: 2 2 |
306 | VO4CX | - | - | - | - | 1件: 296 296 |
307 | Vobarilizumab | 1件: Vobarilizumab Vobarilizumab | 1件: D11005
D11005
| - | - | 1件: 49 49 |
308 | Voclosporin | 1件: Voclosporin Voclosporin | 1件: D09033
D09033
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 |
309 | Volanesorsen | 1件: Volanesorsen Volanesorsen | 1件: D11648
D11648
| 1件: APOC3 APOC3 💬 | 2件: Cholesterol metabolism Cholesterol metabolism, PPAR signaling pathway 💬 | 1件: 265 265 |
310 | VOLANESORSEN SODIUM, ApoC-III Antisense Oligonucleotide | 1件: Volanesorsen Volanesorsen | 1件: D11648
D11648
| 1件: APOC3 APOC3 💬 | 2件: Cholesterol metabolism Cholesterol metabolism, PPAR signaling pathway 💬 | 1件: 265 265 |
311 | Volibris | 1件: Ambrisentan Ambrisentan | 1件: D07077
D07077
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 4件: 51 51, 85, 86, 88 |
312 | VOLIBRIS 10 mg comprimidos recubiertos con película | 1件: Ambrisentan Ambrisentan | 1件: D07077
D07077
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
313 | VOLIBRIS 5 mg comprimidos recubiertos con película | 1件: Ambrisentan Ambrisentan | 1件: D07077
D07077
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
314 | VOLIBRIS® (ambrisentan) | 1件: Ambrisentan Ambrisentan | 1件: D07077
D07077
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
315 | VOLIBRIS™ tablets | 1件: Ambrisentan Ambrisentan | 1件: D07077
D07077
| 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
316 | Volixibat | 1件: Volixibat Volixibat | 1件: D11007
D11007
| - | - | 2件: 93 93, 94 |
317 | Volixibat (formely SHP626, LUM002 or SAR548304B) | 1件: Volixibat Volixibat | 1件: D11007
D11007
| - | - | 1件: 94 94 |
318 | Volixibat potassium | 2件: Potassium Potassium, Volixibat | 2件: D08403
D08403
,
D11007
| - | - | 1件: 94 94 |
319 | VOLMAX*30CPR 4MG R.P. | - | - | - | - | 1件: 3 3 |
320 | Voltaren resinat | - | - | - | - | 1件: 271 271 |
321 | Voltarol | - | - | - | - | 1件: 46 46 |
322 | Voltarol SR | - | - | - | - | 1件: 46 46 |
323 | Voltarol SR (generics also available in the EU) | - | - | - | - | 1件: 46 46 |
324 | Voltrarol SR | - | - | - | - | 1件: 46 46 |
325 | Voluntary Peak Cough Flow Testing | - | - | - | - | 1件: 2 2 |
326 | Von willebrand factor | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 2件: 64 64, 288 |
327 | Von Willebrand factor (Recombinant) | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 |
328 | Von Willebrand factor and coagulation factor VIII in combination | 2件: Beroctocog alfa Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 |
329 | Von Willebrand Factor Antigen | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 |
330 | Von Willebrand Factor Ristocetin Cofactor | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 |
331 | Von Willebrand Faktor | - | - | - | - | 1件: 288 288 |
332 | Voncento | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 |
333 | Voncento, Biostate® | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 |
334 | Voncento® | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 |
335 | VONICOG ALFA | 1件: Vonicog alfa Vonicog alfa | 1件: D08681
D08681
| - | - | 1件: 288 288 |
336 | Vonoprazan | 1件: Vonoprazan Vonoprazan | 1件: D11784
D11784
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 2件: 63 63, 98 |
337 | Voriconazole | 1件: Voriconazole Voriconazole | 1件: D00578
D00578
| - | - | 2件: 60 60, 299 |
338 | Vorinostat | 1件: Vorinostat Vorinostat | 1件: D06320
D06320
| 11件: HDAC1 HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Amyotrophic lateral sclerosis, Apelin signaling pathway, Cell cycle, Chronic myeloid leukemia, Epstein-Barr virus infection, Human papillomavirus infection, Huntington disease, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, Notch signaling pathway, Pathways in cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Viral carcinogenesis 💬 | 3件: 19 19, 75, 96 |
339 | Vorsoritide | - | - | - | - | 1件: 276 276 |
340 | Vortioxetine | 1件: Vortioxetine Vortioxetine | 1件: D10184
D10184
| 7件: HTR1A HTR1A, HTR3A, HTR3B, HTR3C, HTR3D, HTR3E, SLC6A4 💬 | 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, cAMP signaling pathway 💬 | 1件: 6 6 |
341 | Vosoritide | 1件: Vosoritide Vosoritide | 1件: D11190
D11190
| 1件: NPR2 NPR2 💬 | 5件: Metabolic pathways Metabolic pathways, Oxytocin signaling pathway, Purine metabolism, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 276 276 |
342 | Votubia | 1件: Everolimus Everolimus | 1件: D02714
D02714
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 2件: 34 34, 158 |
343 | VPA | - | - | - | - | 1件: 3 3 |
344 | VPD-737 | - | - | - | - | 1件: 36 36 |
345 | VPRIV | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: D09029
D09029
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
346 | VPRIV - 400 U - POLVERE PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: D09029
D09029
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
347 | VPRIV 400 Units powder for solution of infusion | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: D09029
D09029
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
348 | VPRIV ®, | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: D09029
D09029
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
349 | VPRIV® | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: D09029
D09029
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
350 | VR040 | - | - | - | - | 1件: 6 6 |
351 | VR040/Aspirair® inhaler | - | - | - | - | 1件: 6 6 |
352 | VR496 | - | - | - | - | 1件: 299 299 |
353 | VRP700 | - | - | - | - | 1件: 85 85 |
354 | VRS-317 | - | - | - | - | 1件: 78 78 |
355 | VRT-813077 | - | - | - | - | 1件: 299 299 |
356 | VRT-826809 | - | - | - | - | 1件: 299 299 |
357 | VRT-893661 | - | - | - | - | 1件: 299 299 |
358 | VRT-893661 VRT-0893661 | - | - | - | - | 1件: 299 299 |
359 | VSL#3 | - | - | - | - | 4件: 96 96, 97, 107, 291 |
360 | VSL#3 (Original De Simone formulation) | - | - | - | - | 2件: 96 96, 97 |
361 | VSL#3® | - | - | - | - | 2件: 96 96, 97 |
362 | VSN16R | - | - | - | - | 1件: 13 13 |
363 | VSN16R 100mg | - | - | - | - | 1件: 13 13 |
364 | VT-001 | - | - | - | - | 1件: 66 66 |
365 | VT30 | - | - | - | - | 2件: 278 278, 279 |
366 | VTS-270 | - | - | - | - | 1件: 19 19 |
367 | VTX-801 | - | - | - | - | 1件: 171 171 |
368 | VTX002 | - | - | - | - | 1件: 97 97 |
369 | VTX002 is not biologic | - | - | - | - | 1件: 97 97 |
370 | VWD factor VIII concentrate | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 |
371 | VWF replacement therapy with Wilate | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 |
372 | VWF SD-35-DH | - | - | - | - | 1件: 288 288 |
373 | VWF-containing products | - | - | - | - | 1件: 288 288 |
374 | VWF/FVIII products | - | - | - | - | 1件: 288 288 |
375 | VX-121 | - | - | - | - | 1件: 299 299 |
376 | VX-121/TEZ/D-IVA | - | - | - | - | 1件: 299 299 |
377 | VX-121/tezacaftor/deutivacaftor | 2件: Deutivacaftor Deutivacaftor, Tezacaftor | 2件: D11041
D11041
,
D11423
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
378 | VX-147 | - | - | - | - | 1件: 222 222 |
379 | VX-152 | - | - | - | - | 1件: 299 299 |
380 | VX-371 | - | - | - | - | 1件: 299 299 |
381 | VX-371 in hypertonic saline | - | - | - | - | 1件: 299 299 |
382 | VX-371 in saline | - | - | - | - | 1件: 299 299 |
383 | VX-440 | - | - | - | - | 1件: 299 299 |
384 | VX-445 | - | - | - | - | 1件: 299 299 |
385 | VX-445 / TEZ / IVA | - | - | - | - | 1件: 299 299 |
386 | VX-445 / TEZ / IVA FDC | - | - | - | - | 1件: 299 299 |
387 | VX-445 /TEZ/IVA | - | - | - | - | 1件: 299 299 |
388 | VX-445/TEZ/IVA | - | - | - | - | 1件: 299 299 |
389 | VX-509 | - | - | - | - | 1件: 46 46 |
390 | VX-561 | - | - | - | - | 1件: 299 299 |
391 | VX-561 (CTP-656) | - | - | - | - | 1件: 299 299 |
392 | VX-659 | 1件: VX-659 VX-659 | - | - | - | 1件: 299 299 |
393 | VX-659/ TEZ/IVA | 1件: VX-659 VX-659 | - | - | - | 1件: 299 299 |
394 | VX-659/TEZ/IVA | 1件: VX-659 VX-659 | - | - | - | 1件: 299 299 |
395 | VX-659/Tezacaftor/Ivacaftor | 3件: Ivacaftor Ivacaftor, Tezacaftor, VX-659 | 2件: D09916
D09916
,
D11041
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
396 | VX-661 | - | - | - | - | 1件: 299 299 |
397 | VX-661 / VX-770 | - | - | - | - | 1件: 299 299 |
398 | VX-661 Plus Ivacaftor Combination | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
399 | VX-661, VRT-893661 | - | - | - | - | 1件: 299 299 |
400 | VX-661/Ivacaftor | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
401 | VX-661/ivacaftor (VX-770) 100mg/150 mg | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
402 | VX-661/ivacaftor 100 mg/ 150 mg | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
403 | VX-661/ivacaftor 100mg/150 mg | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
404 | VX-661/ivacaftor 100mg/150mg | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
405 | VX-661/ivacaftor 50 mg/ 75 mg | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
406 | VX-661/VX-770 | - | - | - | - | 1件: 299 299 |
407 | VX-661/VX-770 (TEZ/IVA) | - | - | - | - | 1件: 299 299 |
408 | VX-702 | 1件: VX-702 VX-702 | - | - | - | 1件: 46 46 |
409 | VX-745 | - | - | - | - | 1件: 8 8 |
410 | VX-77 | - | - | - | - | 1件: 299 299 |
411 | VX-770 | - | - | - | - | 1件: 299 299 |
412 | VX-770, VRT-8130077 | - | - | - | - | 1件: 299 299 |
413 | VX-770, VRT-813077 | - | - | - | - | 1件: 299 299 |
414 | VX-809 | - | - | - | - | 1件: 299 299 |
415 | VX-809 & VX-770 | - | - | - | - | 1件: 299 299 |
416 | VX-809 / VX-770 | - | - | - | - | 1件: 299 299 |
417 | VX-809, VRT-826809 | - | - | - | - | 1件: 299 299 |
418 | VX-809/VX-770 | - | - | - | - | 1件: 299 299 |
419 | VX-814 | - | - | - | - | 1件: 231 231 |
420 | VX-864 | - | - | - | - | 1件: 231 231 |
421 | VX147 | - | - | - | - | 1件: 222 222 |
422 | VX15/2503 | - | - | - | - | 2件: 8 8, 13 |
423 | VX864 | - | - | - | - | 1件: 231 231 |
424 | VY-AADC01 | - | - | - | - | 1件: 6 6 |
425 | VY-AADC02 | - | - | - | - | 1件: 6 6 |
426 | Vyndaqel | 1件: Tafamidis Tafamidis | 1件: D09673
D09673
| 1件: TTR TTR 💬 | 1件: Thyroid hormone synthesis Thyroid hormone synthesis 💬 | 1件: 28 28 |
427 | Vyndaqel 20mg soft capsule | 1件: Tafamidis Tafamidis | 1件: D09673
D09673
| 1件: TTR TTR 💬 | 1件: Thyroid hormone synthesis Thyroid hormone synthesis 💬 | 1件: 28 28 |
428 | Vyondys 53 | 1件: Golodirsen Golodirsen | 1件: D11707
D11707
| 1件: DMD DMD 💬 | 4件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬 | 1件: 113 113 |